The FDA has approved Zepbound, developed by Eli Lilly, as the first prescription medication to treat moderate-to-severe obstructive sleep apnea in adults with obesity, marking a significant milestone for the company. Originally approved as a weight-loss drug in 2023, Zepbound showed notable results in reducing sleep apnea symptoms, with patients experiencing an average weight loss of 45 pounds and 25 fewer breathing interruptions per hour. Sleep apnea, a condition caused by upper airway blockage during sleep, is associated with loud snoring, daytime fatigue, and increased risks of cardiovascular diseases like hypertension and stroke. Zepbound is a GLP-1 receptor agonist, a drug class known for appetite suppression and blood sugar regulation, which has grown in popularity for addressing multiple health concerns. While CPAP machines remain the most common treatment for sleep apnea, Zepbound’s approval offers a promising new alternative for patients who struggle with traditional options. Continue here.
If you do need a website or your business needs a website, we’re here to bring your dreams to live. Contact us. We would give you the best in quality and the most affordable you would get on the market place. Enjoy our 100% refundable deals. You can’t loose let’s talk about your project.
Kindly reach out on WhatsApp directly and let’s make this decision your most important and best investment post 3 years.
Disclaimer: Full credit to the writer, and the associates.
